首页|期刊导航|Oncology Research|FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells

FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer CellsOA

中文摘要

Background:Fascin actin-bundling protein 1(FSCN1)modulates the expression of key lipogenic enzymes fatty acid synthase(FASN)and stearoyl-CoA desaturase(SCD1)in colorectal cancer(CRC),but the underlying mechanisms remain elusive.Methods:Bioinformatics analyses were performed to evaluate FSCN1 expression and its prognostic value in CRC.Intracellular lipid levels following FSCN1 knockdown were assessed by Nile Red/DAPI co-staining and triglyceride quantification,and further validated by Oil Red O staining of xenograft tumors.Expression levels of key metabolic enzymes were measured by qRT-PCR and Western blotting.RNA sequencing identified FSCN1-associated pathways,which were functionally investigated using pharmacological inhibitors.Results:FSCN1 was significantly upregulated in CRC(p<0.001;AUC=0.796)and was correlated with poorer overall survival(p=0.018).FSCN1 depletion reduced intracellular lipid accumulation,accompanied by downregulation of lipogenicmediators-sterol regulatory element-binding transcription factor 1(SREBF1;protein product:SREBP1),FASN,and SCD1-and upregulation of peroxisomal fatty acid oxidation(FAO)-related factors-peroxisome proliferator-activated receptor alpha(PPARA;protein product:PPARα)and acyl-CoA oxidase 1(ACOX1).Mechanistically,FSCN1 was associated with activation of the protein kinase B/mammalian target of rapamycin(AKT/mTOR)and p38 mitogen-activated protein kinase(p38 MAPK)pathways;pharmacological inhibition with LY294002 or SB203580 phenocopied the lipid-lowering effects of FSCN1 knockdown.Conclusion:Collectively,these findings link FSCN1 to the AKT/mTOR/SREBP1/(FASN/SCD1)lipogenic axis and the p38 MAPK/PPARα/ACOX1 peroxisomal FAO pathway,implicating FSCN1 in lipid metabolic regulation and CRC progression,while suggesting a putative functional regulatory axis and a promising candidate therapeutic target for CRC.

Zhen Li;Xinya Yu;Boning Wu;Jialin Zhang;Xinyu Ju;Yajun Wang;Jieli Song;Qiao Liu;Peng Huang;Qi Ding;Yupeng Wu

Bengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,China Department of Blood Transfusion,The Affiliated Wuxi People’s Hospital of Nanjing Medical University,Wuxi People’s Hospital,Wuxi Medical Center,Nanjing Medical University,Wuxi,ChinaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,ChinaDepartment of Biology,Hefei No.1 Middle School,Hefei,ChinaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,ChinaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,ChinaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,ChinaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,ChinaState Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-Sen University Cancer Center,Guangzhou,ChinaState Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-Sen University Cancer Center,Guangzhou,China Metabolic Innovation Center,Sun Yat-Sen University,Guangzhou,ChinaSchool of Pharmacy,Bengbu Medical University,Bengbu,ChinaBengbu Medical University Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis,School of Laboratory Medicine,Bengbu Medical University,Bengbu,China Department of Biochemistry and Molecular Biology,School of Laboratory Medicine,Bengbu Medical University,Bengbu,China Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment,Bengbu Medical University,Bengbu,China

医药卫生

Colorectal cancerFSCN1AKT/mTOR pathwayp38 MAPK pathwaymetabolic regulation

《Oncology Research》 2026 (10)

P.636-661,26

supported by Natural Science Research Project of Anhui Educational Committee(2022AH040223)Open Funds of State Key Laboratory of Oncology in South China(HN2024-01)2024 Graduate Student Research Innovation Program Project of Bengbu Medical University(Byycx24069).

10.32604/or.2026.084987

评论